Press Releases

Press Releases

MALVERN, Pa., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced the pricing
February 22, 2022
MALVERN, Pa., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it has
February 22, 2022
73% of Americans would like to see additional COVID-19 vaccines be available that are developed from a more traditional method 40% of parents whose children under age 18 are not yet vaccinated say they would be more likely to vaccinate their children if there was a new COVID-19 vaccine developed
February 15, 2022